Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.
The Company's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Alferon LDO. Ampligen is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases.

Employee Rating

1.8More
TypePublic
HQPhiladelphia, US
Founded1990
Size (employees)32 (est)
Websitehemispherx.net
Hemispherx BioPharma was founded in 1990 and is headquartered in Philadelphia, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Hemispherx BioPharma

David R. Strayer

David R. Strayer

Chief Scientific & Medical Officer
Peter W. Rodino

Peter W. Rodino

Executive Director for Governmental Relations, General Counsel and Secretary
Wayne Springate

Wayne Springate

Senior Vice President of Operations
Show more

Hemispherx BioPharma Office Locations

Hemispherx BioPharma has an office in Philadelphia
Philadelphia, (HQ)
1190 One Penn Center 1617 John F Kennedy Blvd
Philadelphia,
500 One Penn Center 1617 John F Kennedy Blvd
Show all (2)
Report incorrect company information

Hemispherx BioPharma Financials and Metrics

Hemispherx BioPharma Revenue

Hemispherx BioPharma's revenue was reported to be $437 k in FY, 2017
USD

Revenue (Q3, 2018)

38.0k

Net income (Q3, 2018)

(3.1m)

EBIT (Q3, 2018)

(3.0m)

Market capitalization (4-Dec-2018)

9.2m

Closing stock price (4-Dec-2018)

0.2

Cash (30-Sep-2018)

4.1m
Hemispherx BioPharma's current market capitalization is $9.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

150.0k197.0k133.0k92.0k437.0k

Revenue growth, %

31%(32%)(31%)

General and administrative expense

7.7m9.1m7.1m7.7m6.6m

R&D expense

8.4m9.0m8.0m5.1m4.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

36.0k76.0k36.0k45.0k36.0k47.0k23.0k39.0k15.0k22.0k84.0k213.0k90.0k56.0k33.0k38.0k

General and administrative expense

2.1m2.5m2.5m2.2m1.9m2.0m1.7m2.4m1.6m1.6m1.7m1.6m1.6m1.6m1.7m1.3m

R&D expense

2.2m2.3m2.3m1.9m2.7m2.4m2.0m1.0m900.0k1.3m1.4m1.1m787.0k855.0k1.3m1.6m

Operating expense total

4.5m5.2m5.1m4.4m4.6m4.9m4.0m3.7m2.8m3.2m3.3m2.9m2.7m2.6m3.3m3.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

803.0k2.2m2.1m2.4m1.4m

Accounts Receivable

24.0k

Inventories

399.0k335.0k

Current Assets

18.6m16.5m10.6m6.9m3.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

1.6m4.1m2.6m1.3m2.9m1.8m1.2m1.0m1.5m4.5m776.0k1.2m503.0k4.0m3.6m4.1m

Accounts Receivable

41.0k98.0k42.0k29.0k35.0k28.0k

Inventories

626.0k

Current Assets

29.6m21.9m20.5m17.7m17.9m17.1m14.0m9.5m10.7m9.3m5.2m4.7m3.7m5.7m5.3m4.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.2m)(17.4m)(15.2m)(7.5m)(8.3m)

Depreciation and Amortization

671.0k665.0k941.0k1.1m948.0k

Inventories

(1.3m)

Accounts Payable

(617.0k)869.0k(196.0k)(326.0k)566.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(13.0m)(3.8m)(8.8m)(13.0m)(3.4m)(8.3m)(12.1m)(2.2m)(3.5m)(6.3m)(2.8m)(5.0m)(6.3m)(2.7m)(5.1m)(8.2m)

Depreciation and Amortization

504.0k167.0k332.0k500.0k180.0k458.0k663.0k300.0k576.0k854.0k261.0k504.0k739.0k216.0k444.0k658.0k

Inventories

453.0k(480.0k)(1.0m)(1.3m)

Accounts Payable

(197.0k)(16.0k)238.0k1.2m236.0k189.0k97.0k182.0k178.0k(202.0k)103.0k85.0k174.0k245.0k126.0k277.0k
USDY, 2018

Financial Leverage

2.4 x
Show all financial metrics
Report incorrect company information

Hemispherx BioPharma Company Life and Culture

Report incorrect company information

Hemispherx BioPharma Frequently Asked Questions

  • When was Hemispherx BioPharma founded?

    Hemispherx BioPharma was founded in 1990.

  • Who are Hemispherx BioPharma key executives?

    Hemispherx BioPharma's key executives are David R. Strayer, Peter W. Rodino and Wayne Springate.

  • How many employees does Hemispherx BioPharma have?

    Hemispherx BioPharma has 32 employees.

  • What is Hemispherx BioPharma revenue?

    Latest Hemispherx BioPharma annual revenue is $437 k.

  • What is Hemispherx BioPharma revenue per employee?

    Latest Hemispherx BioPharma revenue per employee is $13.7 k.

  • Who are Hemispherx BioPharma competitors?

    Competitors of Hemispherx BioPharma include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is Hemispherx BioPharma headquarters?

    Hemispherx BioPharma headquarters is located at 1190 One Penn Center 1617 John F Kennedy Blvd, Philadelphia.

  • Where are Hemispherx BioPharma offices?

    Hemispherx BioPharma has an office in Philadelphia.

  • How many offices does Hemispherx BioPharma have?

    Hemispherx BioPharma has 2 offices.